StockData
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/30
$2.83−11.27 (-79.93%)

Close on Nov 17, 2026Market cap $20.56MP/E –Yield –

Cue Biopharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cue Biopharma's revenue for the twelve months ending Jun 30, 2026 was $37.65M, up 354.4% year over year. For fiscal 2025 it was $27.47M, up 195.7% from the year before. The highest annual figure on record is $27.47M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$27.47M+195.7%
FY2024Dec 31, 2024$9.29M+69.2%
FY2023Dec 31, 2023$5.49M+341.0%
FY2022Dec 31, 2022$1.25M-91.7%
FY2021Dec 31, 2021$14.94M+373.7%
FY2020Dec 31, 2020$3.15M-8.8%
FY2019Dec 31, 2019$3.46M+202.7%
FY2018Dec 31, 2018$1.14M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.88M+166.7%
Q1 FY2026Mar 31, 2026$5.69M+1250.6%
Q4 FY2025Dec 31, 2025$21.94M+1292.3%
Q3 FY2025Sep 30, 2025$2.15M-35.6%
Q2 FY2025Jun 30, 2025$2.95M+11.1%
Q1 FY2025Mar 31, 2025$421.00K-75.5%
Q4 FY2024Dec 31, 2024$1.58M-13.5%
Q3 FY2024Sep 30, 2024$3.34M+58.9%
Q2 FY2024Jun 30, 2024$2.66M+92.3%
Q1 FY2024Mar 31, 2024$1.72M+818.2%
Q4 FY2023Dec 31, 2023$1.82M+1106.0%
Q3 FY2023Sep 30, 2023$2.10M+2988.2%
Q2 FY2023Jun 30, 2023$1.38M+5215.4%
Q1 FY2023Mar 31, 2023$187.00K-81.3%
Q4 FY2022Dec 31, 2022$151.00K-98.2%
Q3 FY2022Sep 30, 2022$68.00K-97.2%
Q2 FY2022Jun 30, 2022$26.00K-99.1%
Q1 FY2022Mar 31, 2022$1.00M-35.6%
Q4 FY2021Dec 31, 2021$8.25M+1636.6%
Q3 FY2021Sep 30, 2021$2.40M+240.2%
Q2 FY2021Jun 30, 2021$2.74M+154.8%
Q1 FY2021Mar 31, 2021$1.55M+72.6%
Q4 FY2020Dec 31, 2020$475.33K-54.7%
Q3 FY2020Sep 30, 2020$704.00K-28.5%
Q2 FY2020Jun 30, 2020$1.08M+1.9%
Q1 FY2020Mar 31, 2020$900.00K+143.2%
Q4 FY2019Dec 31, 2019$1.05M+217.4%
Q3 FY2019Sep 30, 2019$984.00K+119.2%
Q2 FY2019Jun 30, 2019$1.06M+513.4%
Q1 FY2019Mar 31, 2019$370.00K–
Q4 FY2018Dec 31, 2018$330.60K–
Q3 FY2018Sep 30, 2018$449.00K–
Q2 FY2018Jun 30, 2018$172.00K–

More Cue Biopharma figures

See a number that looks wrong?